A Phase 2 interventional study of Elsubrutinib and Upadacitinib in Rheumatoid Arthritis (RA), sponsored by AbbVie. Completed at 115 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-03.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing upadacitinib in Arthritis, Rheumatoid — 3 open to participants now, 3 under way, none of them phase 3. upadacitinib · Arthritis, Rheumatoid.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, this one is the 13th largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 2, and was the 11th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 19 studies testing upadacitinib in Arthritis, Rheumatoid are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Toulouse · Sites in France
Ages 18–65
AbbVie
Ages 18+
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 8 · Phase 4 3
First in 2012; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 242 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 300 across the 19 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 7 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 18th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2018, is one of 16 in phase 2, and was the 63rd registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing upadacitinib in Arthritis, Rheumatoid, from their registry updates:
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
This was a phase 2 study to evaluate the safety and efficacy of elsubrutinib (ELS) and ABBV-599 (ELS plus upadacitinib [UPA]) vs placebo on a background of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) for the treatment of signs and symptoms of rheumatoid arthritis (RA) at 12 weeks in biological disease-modifying anti-rheumatic drugs (bDMARD)-inadequate response (bDMARD-IR) or bDMARD-intolerant participants with moderately to severely active RA and to define optimal dose for further development.
This was a 12-week, randomized, double-blind, parallel-group, Phase 2, dose exploratory, multicenter study. Participants who met eligibility criteria were randomized in a 3:2:2:2:2:1 ratio to 1 of 6 treatment groups: ABBV-599 [UPA 15 mg/ELS 60 mg]); ELS 60 mg/UPA placebo; ELS 20 mg/UPA placebo; ELS 5 mg/UPA placebo; UPA 15 mg/ELS placebo; and ELS placebo/UPA placebo. The study included a 35-day maximum screening period and a 12-week treatment period with 30-day follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant meets the following minimum disease activity criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo capsule for elsubrutinib once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
Drug: Placebo for elsubrutinib · Drug: Placebo for upadacitinib
15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; 60 mg elsubrutinib capsule once a day by mouth for 12 weeks
Drug: Elsubrutinib · Drug: Upadacitinib
60 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
Drug: Elsubrutinib · Drug: Placebo for upadacitinib
20 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
Drug: Elsubrutinib · Drug: Placebo for upadacitinib
5 mg elsubrutinib capsule once a day by mouth for 12 weeks; placebo film-coated tablet for upadacitinib once a day by mouth for 12 weeks
Drug: Elsubrutinib · Drug: Placebo for upadacitinib
15 mg film-coated upadacitinib tablet once a day by mouth for 12 weeks; placebo capsule for elsubrutinib once a day by mouth for 12 weeks
Drug: Upadacitinib · Drug: Placebo for elsubrutinib
Elsubrutinib capsule will be administered orally.
Also known as: ABBV-105
Upadacitinib tablet will be administered orally.
Also known as: ABT-494
Placebo capsule for elsubrutinib will be administered orally.
Placebo tablet for upadacitinib will be administered orally.
Change From Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline indicates improvement in disease activity.
Time frame: Baseline, Week 12
Change From Baseline in Clinical Disease Activity Index (CDAI)
The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. A negative change from baseline indicates improvement in disease activity.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change From Baseline in Simplified Disease Activity Index (SDAI)
The SDAI is a validated measure of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global disease activity assessed by the participant on a visual analogue scale from 0 to 10 (cm), global disease activity assessed by an investigator on a visual analogue scale from 0 to 10 (cm), and serum levels of C-reactive protein (CRP; mg/dL) were included in the SDAI score. Scores on the SDAI range from 0 to 86.with higher scores indicating higher disease activity. A negative change from baseline indicates improvement in disease activity.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.
Time frame: At Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.
Time frame: At Week 12
Percentage of Participants Achieving Low Disease Activity (LDA) Based on Clinical Disease Activity Index (CDAI) Criteria
The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Low Disease Activity (LDA) based on CDAI is defined as achieving a CDAI of less than or equal to 10.
Time frame: Week 2, Week 4, Week 8, and Week 12
Percentage of Participants Achieving Complete Remission (CR) Based on Clinical Disease Activity Index (CDAI) Criteria
The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Complete Remission (CR) based on CDAI is defined as achieving a CDAI of less than or equal to 2.8.
Time frame: Week 2, Week 4, Week 8, and Week 12
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the American College of Rheumatology 20% response (ACR20) criteria: 1. ≥ 20% improvement in 68-tender joint count 2. ≥ 20% improvement in 66-swollen joint count and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the American College of Rheumatology 50% response (ACR50) criteria: 1. ≥ 50% improvement in 68-tender joint count 2. ≥ 50% improvement in 66-swollen joint count and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the American College of Rheumatology 70% response (ACR70) criteria: 1. ≥ 70% improvement in 68-tender joint count 2. ≥ 70% improvement in 66-swollen joint count and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change From Baseline in Tender Joint Count 68 (TJC68)
Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change From Baseline in Swollen Joint Count 66 (SJC66)
Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change From Baseline in Participant's Assessment of Pain (Visual Analog Scale [VAS])
Participants rated their pain on a visual analogue scale (VAS) of 0 to 100 (mm), with 0 representing no pain and 100 representing the worst possible pain. Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change From Baseline in Patient's Global Assessment of Disease Activity (PGA)
Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change From Baseline in Physician's Global Assessment of Disease Activity (PhGA)
The physician assessed a participant's disease activity at the time of the visit using a Physician's Global Assessment of Disease visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from baseline in the overall score indicates improvement.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP)
C-reactive protein is a blood test marker for inflammation in the body, and levels rise in response to inflammation. A negative change from baseline in indicates improvement.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change From Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP])
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline indicates improvement in disease activity.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change From Baseline in Disease Activity Score 28 Erythrocyte Sedimentation Rate (DAS28- ESR)
The DAS28-ESR is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 100 mm) are included in the DAS28 -ESR score. Scores on the DAS28-ESR range from 0 to 10; higher scores indicate more disease activity.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Change From Baseline in Morning Stiffness Severity
Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Percentage of Participants Achieving Minimal Clinically Important Difference (MCID) in Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. The minimal clinically important difference (MCID) in HAQ-DI is defined as change from Baseline ≤ -0.22 for rheumatoid arthritis.
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
Percentage of Participants Achieving American College of Rheumatology/European League Against Rheumatism (EULAR) Boolean Remission
The EULAR Boolean-based definition of remission is as follows: at any time point, a participant must satisfy all of the following: tender joint count ≤1, swollen joint count ≤1, C-reactive protein ≤1 mg/dl and Patient Global Assessment (PGA) ≤1 (on a 0-10 scale).
Time frame: Baseline, Week 2, Week 4, Week 8, and Week 12
| Milestone | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Started | 19 | 62 | 41 | 39 | 41 | 40 |
| Completed | 17 | 58 | 38 | 34 | 35 | 38 |
| Not completed | 2 | 4 | 3 | 5 | 6 | 2 |
| Withdrew: Adverse event | 1 | 1 | 1 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 | 2 | 4 | 0 | 1 |
| Withdrew: Other, not specified | 0 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 3 | 0 |
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline indicates improvement in disease activity.
| units on a scale | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Change From Baseline in Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12 | -1.12 (-1.64 to -0.60) | -2.56 (-2.86 to -2.26) | -1.52 (-1.89 to -1.15) | -1.32 (-1.71 to -0.93) | -1.33 (-1.70 to -0.97) | -2.87 (-3.23 to -2.51) |
The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. A negative change from baseline indicates improvement in disease activity.
| units on a scale | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | -6.08 (-10.48 to -1.67) | -16.00 (-18.53 to -13.47) | -8.95 (-11.99 to -5.91) | -7.36 (-10.44 to -4.27) | -8.38 (-11.48 to -5.28) | -14.03 (-17.04 to -11.02) |
| Week 4 | -11.60 (-16.38 to -6.82) | -20.24 (-22.97 to -17.50) | -11.67 (-15.01 to -8.34) | -10.10 (-13.50 to -6.70) | -12.90 (-16.22 to -9.58) | -20.30 (-23.57 to -17.03) |
| Week 8 | -12.46 (-17.52 to -7.40) | -24.95 (-27.86 to -22.05) | -15.07 (-18.65 to -11.49) | -17.10 (-20.83 to -13.38) | -14.84 (-18.42 to -11.26) | -23.72 (-27.20 to -20.24) |
| Week 12 | -14.57 (-19.77 to -9.36) | -27.00 (-30.05 to -23.95) | -17.50 (-21.22 to -13.78) | -16.70 (-20.62 to -12.78) | -16.51 (-20.27 to -12.75) | -28.85 (-32.48 to -25.21) |
The SDAI is a validated measure of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global disease activity assessed by the participant on a visual analogue scale from 0 to 10 (cm), global disease activity assessed by an investigator on a visual analogue scale from 0 to 10 (cm), and serum levels of C-reactive protein (CRP; mg/dL) were included in the SDAI score. Scores on the SDAI range from 0 to 86.with higher scores indicating higher disease activity. A negative change from baseline indicates improvement in disease activity.
| units on a scale | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | -6.17 (-10.67 to -1.67) | -17.01 (-19.60 to -14.43) | -8.79 (-11.89 to -5.68) | -7.42 (-10.57 to -4.26) | -8.54 (-11.71 to -5.38) | -15.30 (-18.37 to -12.22) |
| Week 4 | -11.80 (-16.67 to -6.93) | -21.24 (-24.02 to -18.45) | -11.46 (-14.85 to -8.06) | -10.15 (-13.61 to -6.68) | -12.87 (-16.25 to -9.49) | -21.59 (-24.92 to -18.26) |
| Week 8 | -12.15 (-17.35 to -6.95) | -25.96 (-28.95 to -22.98) | -15.26 (-18.94 to -11.57) | -17.32 (-21.17 to -13.46) | -15.21 (-18.89 to -11.53) | -25.07 (-28.65 to -21.49) |
| Week 12 | -14.44 (-19.84 to -9.04) | -28.06 (-31.22 to -24.89) | -18.01 (-21.86 to -14.15) | -17.12 (-21.20 to -13.05) | -16.73 (-20.65 to -12.81) | -29.65 (-33.42 to -25.88) |
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.
| percentage of participants | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Clinical Remission (CR) Based on Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12 | 10.5 (3.55 to 27.35) | 32.3 (23.41 to 42.59) | 19.5 (11.36 to 31.44) | 7.7 (3.12 to 17.76) | 9.8 (4.46 to 20.04) | 42.5 (30.52 to 55.43) |
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. Low Disease Activity (LDA) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than or equal to 3.2.
| percentage of participants | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Low Disease Activity (LDA) Based on Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) at Week 12 | 21.1 (9.82 to 39.50) | 41.9 (32.18 to 52.37) | 22.0 (13.24 to 34.13) | 10.3 (4.69 to 20.98) | 14.6 (7.76 to 25.89) | 55.0 (42.16 to 67.21) |
The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Low Disease Activity (LDA) based on CDAI is defined as achieving a CDAI of less than or equal to 10.
| percentage of participants | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | 10.5 (3.55 to 27.35) | 16.1 (9.89 to 25.20) | 9.8 (4.46 to 20.04) | 0 (0.00 to 6.49) | 2.4 (0.55 to 10.22) | 12.5 (6.22 to 23.53) |
| Week 4 | 10.5 (3.55 to 27.35) | 29.0 (20.59 to 39.23) | 12.2 (6.06 to 23.01) | 7.7 (3.12 to 17.76) | 12.2 (6.06 to 23.01) | 22.5 (13.59 to 34.90) |
| Week 8 | 5.3 (1.18 to 20.50) | 46.8 (36.71 to 57.11) | 17.1 (9.53 to 28.69) | 20.5 (11.96 to 32.89) | 24.4 (15.17 to 36.78) | 35.0 (23.91 to 47.99) |
| Week 12 | 26.3 (13.44 to 45.09) | 37.1 (27.74 to 47.53) | 34.1 (23.29 to 46.97) | 17.9 (10.03 to 30.02) | 17.1 (9.53 to 28.69) | 57.5 (44.57 to 69.48) |
The CDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. Complete Remission (CR) based on CDAI is defined as achieving a CDAI of less than or equal to 2.8.
| percentage of participants | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | 0 (0.00 to 12.46) | 3.2 (1.07 to 9.29) | 0 (0.00 to 6.19) | 0 (0.00 to 6.49) | 0 (0.00 to 6.19) | 0 (0.00 to 6.34) |
| Week 4 | 0 (0.00 to 12.46) | 6.5 (2.93 to 13.62) | 2.4 (0.55 to 10.22) | 2.6 (0.57 to 10.71) | 0 (0.00 to 6.19) | 2.5 (0.56 to 10.46) |
| Week 8 | 0 (0.00 to 12.46) | 12.9 (7.43 to 21.48) | 7.3 (2.96 to 16.96) | 2.6 (0.57 to 10.71) | 2.4 (0.55 to 10.22) | 12.5 (6.22 to 23.53) |
| Week 12 | 5.3 (1.18 to 20.50) | 14.5 (8.65 to 23.35) | 7.3 (2.96 to 16.96) | 5.1 (1.71 to 14.37) | 0 (0.00 to 6.19) | 15.0 (7.96 to 26.47) |
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the American College of Rheumatology 20% response (ACR20) criteria: 1. ≥ 20% improvement in 68-tender joint count 2. ≥ 20% improvement in 66-swollen joint count and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)
| percentage of participants | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | 21.1 (9.82 to 39.50) | 45.2 (35.19 to 55.54) | 24.4 (15.17 to 36.78) | 12.8 (6.38 to 24.08) | 14.6 (7.76 to 25.89) | 52.5 (39.77 to 64.91) |
| Week 4 | 42.1 (25.63 to 60.55) | 51.6 (41.33 to 61.76) | 29.3 (19.16 to 41.94) | 23.1 (13.95 to 35.70) | 22.0 (13.24 to 34.13) | 55.0 (42.16 to 67.21) |
| Week 8 | 36.8 (21.37 to 55.59) | 64.5 (54.11 to 73.71) | 39.0 (27.55 to 51.86) | 30.8 (20.20 to 43.84) | 39.0 (27.55 to 51.86) | 67.5 (54.55 to 78.23) |
| Week 12 | 47.4 (30.07 to 65.33) | 64.5 (54.11 to 73.71) | 41.5 (29.72 to 54.26) | 30.8 (20.20 to 43.84) | 34.1 (23.29 to 46.97) | 72.5 (59.75 to 82.40) |
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the American College of Rheumatology 50% response (ACR50) criteria: 1. ≥ 50% improvement in 68-tender joint count 2. ≥ 50% improvement in 66-swollen joint count and 3. ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)
| percentage of participants | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | 0 (0.00 to 12.46) | 16.1 (9.89 to 25.20) | 4.9 (1.63 to 13.71) | 0 (0.00 to 6.49) | 0 (0.00 to 6.19) | 12.5 (6.22 to 23.53) |
| Week 4 | 10.5 (3.55 to 27.35) | 19.4 (12.46 to 28.82) | 17.1 (9.53 to 28.69) | 2.6 (0.57 to 10.71) | 4.9 (1.63 to 13.71) | 30.0 (19.66 to 42.87) |
| Week 8 | 5.3 (1.18 to 20.50) | 41.9 (32.18 to 52.37) | 19.5 (11.36 to 31.44) | 12.8 (6.38 to 24.08) | 7.3 (2.96 to 16.96) | 40.0 (28.29 to 52.98) |
| Week 12 | 21.1 (9.82 to 39.50) | 45.2 (35.19 to 55.54) | 29.3 (19.16 to 41.94) | 12.8 (6.38 to 24.08) | 17.1 (9.53 to 28.69) | 47.5 (35.09 to 60.23) |
Participants who met the following 3 conditions for improvement from baseline were classified as meeting the American College of Rheumatology 70% response (ACR70) criteria: 1. ≥ 70% improvement in 68-tender joint count 2. ≥ 70% improvement in 66-swollen joint count and 3. ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient's Assessment of Pain (Visual Analog Scale \[VAS\]) * Patient's Global Assessment of Disease Activity (PtGA) * Physician's Global Assessment of Disease Activity (PhGA) * Health Assessment Questionnaire Disability Index (HAQ-DI) * High-sensitivity C-reactive protein (hsCRP)
| percentage of participants | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | 0 (0.00 to 12.46) | 8.1 (3.98 to 15.66) | 2.4 (0.55 to 10.22) | 0 (0.00 to 6.49) | 0 (0.00 to 6.19) | 0 (0.00 to 6.34) |
| Week 4 | 0 (0.00 to 12.46) | 9.7 (5.09 to 17.64) | 4.9 (1.63 to 13.71) | 2.6 (0.57 to 10.71) | 0 (0.00 to 6.19) | 15.0 (7.96 to 26.47) |
| Week 8 | 0 (0.00 to 12.46) | 17.7 (11.16 to 27.02) | 4.9 (1.63 to 13.71) | 2.6 (0.57 to 10.71) | 0 (0.00 to 6.19) | 25.0 (15.57 to 37.60) |
| Week 12 | 15.8 (6.49 to 33.62) | 25.8 (17.81 to 35.82) | 14.6 (7.76 to 25.89) | 5.1 (1.71 to 14.37) | 9.8 (4.46 to 20.04) | 27.5 (17.60 to 40.25) |
Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.
| tender joint counts | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | -2.47 (-6.10 to 1.16) | -8.42 (-10.53 to -6.31) | -3.65 (-6.23 to -1.07) | -3.86 (-6.46 to -1.26) | -4.88 (-7.43 to -2.33) | -8.57 (-11.09 to -6.05) |
| Week 4 | -9.21 (-13.08 to -5.34) | -11.86 (-14.10 to -9.62) | -5.16 (-7.93 to -2.39) | -5.39 (-8.18 to -2.60) | -8.08 (-10.77 to -5.39) | -12.76 (-15.46 to -10.06) |
| Week 8 | -8.82 (-12.85 to -4.79) | -15.44 (-17.75 to -13.12) | -8.43 (-11.31 to -5.55) | -10.83 (-13.78 to -7.88) | -9.08 (-11.88 to -6.27) | -14.76 (-17.56 to -11.97) |
| Week 12 | -8.47 (-12.81 to -4.12) | -16.33 (-18.84 to -13.83) | -9.14 (-12.23 to -6.05) | -9.33 (-12.55 to -6.12) | -12.58 (-15.64 to -9.52) | -17.56 (-20.58 to -14.53) |
Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.
| swollen joint counts | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | -3.12 (-5.20 to -1.05) | -6.06 (-7.26 to -4.86) | -3.61 (-5.08 to -2.14) | -3.30 (-4.78 to -1.82) | -4.13 (-5.60 to -2.67) | -6.02 (-7.46 to -4.58) |
| Week 4 | -4.70 (-6.92 to -2.49) | -7.96 (-9.24 to -6.68) | -5.11 (-6.69 to -3.53) | -4.67 (-6.27 to -3.07) | -6.05 (-7.60 to -4.51) | -8.81 (-10.35 to -7.26) |
| Week 8 | -4.32 (-6.57 to -2.06) | -10.28 (-11.57 to -8.99) | -6.15 (-7.77 to -4.54) | -8.08 (-9.74 to -6.42) | -7.58 (-9.15 to -6.00) | -10.11 (-11.68 to -8.55) |
| Week 12 | -5.58 (-8.05 to -3.11) | -10.86 (-12.29 to -9.44) | -6.68 (-8.44 to -4.92) | -7.85 (-9.70 to -6.01) | -8.59 (-10.35 to -6.83) | -11.14 (-12.86 to -9.42) |
Participants rated their pain on a visual analogue scale (VAS) of 0 to 100 (mm), with 0 representing no pain and 100 representing the worst possible pain. Negative values indicate improvement from baseline.
| units on a scale | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | -14.97 (-22.80 to -7.14) | -24.02 (-28.63 to -19.41) | -10.22 (-15.81 to -4.63) | -8.78 (-14.49 to -3.07) | -7.61 (-13.12 to -2.11) | -15.99 (-21.49 to -10.48) |
| Week 4 | -20.87 (-29.60 to -12.14) | -28.17 (-33.28 to -23.07) | -12.95 (-19.27 to -6.63) | -8.41 (-14.85 to -1.97) | -9.91 (-15.93 to -3.88) | -25.58 (-31.69 to -19.48) |
| Week 8 | -16.21 (-25.97 to -6.45) | -31.86 (-37.50 to -26.22) | -20.92 (-27.96 to -13.88) | -11.12 (-18.46 to -3.79) | -13.90 (-20.64 to -7.16) | -30.70 (-37.47 to -23.92) |
| Week 12 | -23.37 (-33.74 to -13.01) | -32.27 (-38.32 to -26.23) | -19.52 (-26.97 to -12.06) | -10.46 (-18.38 to -2.55) | -17.84 (-25.13 to -10.55) | -38.34 (-45.57 to -31.12) |
Participants rated their disease activity for the past 24 hours using a Patient's Global Assessment of Disease Activity Global visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.
| units on a scale | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | -11.87 (-20.12 to -3.63) | -23.44 (-28.31 to -18.57) | -11.16 (-17.07 to -5.25) | -6.47 (-12.51 to -0.44) | -5.95 (-11.76 to -0.14) | -14.76 (-20.56 to -8.95) |
| Week 4 | -20.93 (-29.91 to -11.94) | -25.97 (-31.24 to -20.70) | -12.79 (-19.32 to -6.26) | -7.15 (-13.79 to -0.50) | -8.73 (-14.94 to -2.51) | -23.02 (-29.31 to -16.73) |
| Week 8 | -15.14 (-25.37 to -4.91) | -28.05 (-33.97 to -22.13) | -17.25 (-24.65 to -9.84) | -6.27 (-14.00 to 1.45) | -14.25 (-21.34 to -7.17) | -26.79 (-33.90 to -19.69) |
| Week 12 | -19.55 (-30.15 to -8.95) | -30.52 (-36.72 to -24.32) | -19.47 (-27.13 to -11.81) | -8.45 (-16.58 to -0.33) | -16.40 (-23.89 to -8.92) | -33.53 (-40.94 to -26.13) |
The physician assessed a participant's disease activity at the time of the visit using a Physician's Global Assessment of Disease visual analogue scale (VAS). The range is 0 to 100 mm, with 0 representing no disease activity and 100 representing severe disease activity. Negative values indicate improvement from baseline.
| units on a scale | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | -16.31 (-24.67 to -7.96) | -22.35 (-27.10 to -17.60) | -19.01 (-24.74 to -13.27) | -16.12 (-21.97 to -10.26) | -11.64 (-17.44 to -5.84) | -24.71 (-30.37 to -19.05) |
| Week 4 | -25.20 (-33.52 to -16.89) | -33.54 (-38.26 to -28.82) | -25.33 (-31.11 to -19.55) | -19.59 (-25.49 to -13.69) | -18.31 (-24.05 to -12.56) | -34.17 (-39.86 to -28.49) |
| Week 8 | -24.47 (-32.71 to -16.22) | -40.00 (-44.71 to -35.29) | -30.06 (-35.91 to -24.22) | -33.93 (-39.99 to -27.87) | -25.21 (-31.03 to -19.40) | -41.02 (-46.69 to -35.36) |
| Week 12 | -23.19 (-31.69 to -14.69) | -46.98 (-52.00 to -41.96) | -30.15 (-36.28 to -24.03) | -31.68 (-38.19 to -25.18) | -24.55 (-30.75 to -18.36) | -50.89 (-56.87 to -44.91) |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. A negative change from baseline in the overall score indicates improvement.
| units on a scale | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | -0.22 (-0.37 to -0.06) | -0.34 (-0.43 to -0.25) | -0.13 (-0.24 to -0.02) | -0.06 (-0.17 to 0.05) | -0.16 (-0.27 to -0.05) | -0.22 (-0.33 to -0.11) |
| Week 4 | -0.36 (-0.53 to -0.18) | -0.39 (-0.49 to -0.29) | -0.11 (-0.23 to 0.02) | -0.14 (-0.27 to -0.02) | -0.21 (-0.33 to -0.09) | -0.33 (-0.45 to -0.20) |
| Week 8 | -0.24 (-0.44 to -0.05) | -0.47 (-0.59 to -0.36) | -0.29 (-0.43 to -0.15) | -0.15 (-0.30 to -0.00) | -0.15 (-0.29 to -0.02) | -0.47 (-0.61 to -0.33) |
| Week 12 | -0.30 (-0.52 to -0.08) | -0.52 (-0.65 to -0.39) | -0.31 (-0.46 to -0.15) | -0.12 (-0.28 to 0.05) | -0.18 (-0.33 to -0.03) | -0.54 (-0.70 to -0.39) |
C-reactive protein is a blood test marker for inflammation in the body, and levels rise in response to inflammation. A negative change from baseline in indicates improvement.
| mg/L | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | -0.51 (-4.82 to 3.81) | -9.29 (-11.79 to -6.80) | 2.26 (-0.81 to 5.33) | -0.34 (-3.43 to 2.74) | -0.72 (-3.74 to 2.30) | -12.27 (-15.26 to -9.27) |
| Week 4 | 1.54 (-3.72 to 6.79) | -10.08 (-13.08 to -7.08) | 2.71 (-1.05 to 6.46) | -0.78 (-4.58 to 3.02) | 0.72 (-2.91 to 4.35) | -12.59 (-16.27 to -8.92) |
| Week 8 | 3.23 (-1.56 to 8.03) | -9.97 (-12.70 to -7.24) | -1.39 (-4.83 to 2.05) | -2.58 (-6.15 to 1.00) | -2.93 (-6.26 to 0.39) | -13.13 (-16.46 to -9.81) |
| Week 12 | 1.45 (-5.10 to 8.00) | -10.95 (-14.73 to -7.18) | -4.58 (-9.26 to 0.09) | -5.78 (-10.77 to -0.78) | -0.81 (-5.58 to 3.97) | -7.44 (-12.03 to -2.86) |
The DAS28-CRP is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100 mm), and high-sensitivity C-reactive protein (hsCRP; in mg/L). Scores on the DAS28-CRP range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from baseline indicates improvement in disease activity.
| units on a scale | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | -0.46 (-0.83 to -0.10) | -1.53 (-1.75 to -1.31) | -0.63 (-0.89 to -0.36) | -0.44 (-0.71 to -0.18) | -0.56 (-0.82 to -0.30) | -1.43 (-1.69 to -1.17) |
| Week 4 | -0.90 (-1.33 to -0.47) | -1.96 (-2.21 to -1.71) | -0.87 (-1.18 to -0.56) | -0.68 (-1.00 to -0.36) | -0.82 (-1.11 to -0.52) | -1.98 (-2.28 to -1.67) |
| Week 8 | -0.78 (-1.27 to -0.29) | -2.40 (-2.68 to -2.11) | -1.21 (-1.56 to -0.86) | -1.24 (-1.61 to -0.87) | -1.11 (-1.45 to -0.77) | -2.34 (-2.68 to -2.00) |
| Week 12 | -1.12 (-1.64 to -0.60) | -2.56 (-2.86 to -2.26) | -1.52 (-1.89 to -1.15) | -1.32 (-1.71 to -0.93) | -1.33 (-1.70 to -0.97) | -2.87 (-3.23 to -2.51) |
The DAS28-ESR is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 100 mm) are included in the DAS28 -ESR score. Scores on the DAS28-ESR range from 0 to 10; higher scores indicate more disease activity.
| units on a scale | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | -0.46 (-0.82 to -0.09) | -1.48 (-1.69 to -1.26) | -0.52 (-0.79 to -0.26) | -0.46 (-0.74 to -0.19) | -0.57 (-0.83 to -0.32) | -1.32 (-1.58 to -1.06) |
| Week 4 | -0.86 (-1.30 to -0.43) | -1.93 (-2.19 to -1.68) | -0.79 (-1.11 to -0.48) | -0.59 (-0.91 to -0.26) | -0.92 (-1.23 to -0.62) | -1.90 (-2.20 to -1.59) |
| Week 8 | -0.80 (-1.29 to -0.31) | -2.41 (-2.69 to -2.12) | -1.07 (-1.42 to -0.71) | -1.15 (-1.52 to -0.78) | -1.20 (-1.54 to -0.86) | -2.31 (-2.65 to -1.97) |
| Week 12 | -1.18 (-1.71 to -0.64) | -2.53 (-2.84 to -2.22) | -1.41 (-1.80 to -1.03) | -1.24 (-1.65 to -0.83) | -1.44 (-1.82 to -1.06) | -2.88 (-3.25 to -2.50) |
Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.
| units on a scale | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | -1.76 (-2.54 to -0.98) | -2.02 (-2.48 to -1.56) | -0.91 (-1.47 to -0.35) | -0.68 (-1.26 to -0.11) | -0.59 (-1.15 to -0.04) | -1.84 (-2.40 to -1.29) |
| Week 4 | -1.76 (-2.63 to -0.90) | -2.71 (-3.22 to -2.21) | -0.82 (-1.45 to -0.20) | -0.83 (-1.47 to -0.19) | -1.08 (-1.67 to -0.48) | -2.51 (-3.13 to -1.90) |
| Week 8 | -1.67 (-2.56 to -0.77) | -3.07 (-3.59 to -2.55) | -1.30 (-1.94 to -0.65) | -0.97 (-1.64 to -0.30) | -1.50 (-2.11 to -0.88) | -3.07 (-3.70 to -2.44) |
| Week 12 | -1.61 (-2.60 to -0.63) | -3.23 (-3.81 to -2.65) | -1.27 (-1.99 to -0.56) | -1.30 (-2.06 to -0.55) | -1.66 (-2.36 to -0.97) | -3.36 (-4.06 to -2.67) |
The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability. The minimal clinically important difference (MCID) in HAQ-DI is defined as change from Baseline ≤ -0.22 for rheumatoid arthritis.
| percentage of participants | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | 52.6 (34.67 to 69.93) | 51.6 (41.33 to 61.76) | 36.6 (25.40 to 49.43) | 30.8 (20.20 to 43.84) | 36.6 (25.40 to 49.43) | 52.5 (39.77 to 64.91) |
| Week 4 | 68.4 (49.55 to 82.70) | 54.8 (44.46 to 64.81) | 34.1 (23.29 to 46.97) | 41.0 (29.07 to 54.15) | 53.7 (41.02 to 65.84) | 45.0 (32.79 to 57.84) |
| Week 8 | 52.6 (34.67 to 69.93) | 58.1 (47.63 to 67.82) | 51.2 (38.71 to 63.58) | 51.3 (38.47 to 63.93) | 36.6 (25.40 to 49.43) | 65.0 (52.01 to 76.09) |
| Week 12 | 47.4 (30.07 to 65.33) | 58.1 (47.63 to 67.82) | 53.7 (41.02 to 65.84) | 43.6 (31.37 to 56.64) | 43.9 (31.93 to 56.63) | 55.0 (42.16 to 67.21) |
The EULAR Boolean-based definition of remission is as follows: at any time point, a participant must satisfy all of the following: tender joint count ≤1, swollen joint count ≤1, C-reactive protein ≤1 mg/dl and Patient Global Assessment (PGA) ≤1 (on a 0-10 scale).
| percentage of participants | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| Week 2 | 0 (0.00 to 12.46) | 1.6 (0.36 to 6.91) | 0 (0.00 to 6.19) | 0 (0.00 to 6.49) | 0 (0.00 to 6.19) | 0 (0.00 to 6.34) |
| Week 4 | 0 (0.00 to 12.46) | 6.5 (2.93 to 13.62) | 2.4 (0.55 to 10.22) | 0 (0.00 to 6.49) | 0 (0.00 to 6.19) | 2.5 (0.56 to 10.46) |
| Week 8 | 0 (0.00 to 12.46) | 6.5 (2.93 to 13.62) | 2.4 (0.55 to 10.22) | 5.1 (1.71 to 14.37) | 0 (0.00 to 6.19) | 12.5 (6.22 to 23.53) |
| Week 12 | 0 (0.00 to 12.46) | 11.3 (6.24 to 19.58) | 9.8 (4.46 to 20.04) | 2.6 (0.57 to 10.71) | 2.4 (0.55 to 10.22) | 10.0 (4.57 to 20.50) |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 30 days after last study drug administration, up to 16 weeks. In addition, serious adverse events and protocol-related nonserious adverse events were collected from the time the participant signed the study-specific informed consent.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ELS Placebo/UPA Placebo | 0/19 (0%) | 1/19 (5.3%) | 10/19 (52.6%) |
| UPA 15 mg/ELS 60 mg | 0/62 (0%) | 0/62 (0%) | 7/62 (11.3%) |
| ELS 60 mg/UPA Placebo | 0/41 (0%) | 0/41 (0%) | 17/41 (41.5%) |
| ELS 20 mg/UPA Placebo | 0/39 (0%) | 2/39 (5.1%) | 10/39 (25.6%) |
| ELS 5 mg/UPA Placebo | 1/41 (2.4%) | 3/41 (7.3%) | 8/41 (19.5%) |
| UPA 15 mg/ELS Placebo | 0/40 (0%) | 0/40 (0%) | 9/40 (22.5%) |
| Event | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| PROSTATIC SPECIFIC ANTIGEN INCREASEDInvestigations | 1/19 | 0/62 | 0/41 | 0/39 | 0/41 | 0/40 |
| CORONARY ARTERY DISEASECardiac disorders | 0/19 | 0/62 | 0/41 | 1/39 | 0/41 | 0/40 |
| LUMBAR RADICULOPATHYNervous system disorders | 0/19 | 0/62 | 0/41 | 1/39 | 0/41 | 0/40 |
| CARDIAC ARRESTCardiac disorders | 0/19 | 0/62 | 0/41 | 0/39 | 1/41 | 0/40 |
| PYELONEPHRITISInfections and infestations | 0/19 | 0/62 | 0/41 | 0/39 | 1/41 | 0/40 |
| CLAVICLE FRACTUREInjury, poisoning and procedural complications | 0/19 | 0/62 | 0/41 | 0/39 | 1/41 | 0/40 |
| RIB FRACTUREInjury, poisoning and procedural complications | 0/19 | 0/62 | 0/41 | 0/39 | 1/41 | 0/40 |
| ROAD TRAFFIC ACCIDENTInjury, poisoning and procedural complications | 0/19 | 0/62 | 0/41 | 0/39 | 1/41 | 0/40 |
| Event | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo |
|---|---|---|---|---|---|---|
| RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders | 2/19 | 0/62 | 3/41 | 3/39 | 3/41 | 0/40 |
| URINARY TRACT INFECTIONInfections and infestations | 0/19 | 0/62 | 4/41 | 2/39 | 2/41 | 3/40 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/19 | 4/62 | 2/41 | 3/39 | 2/41 | 2/40 |
| DIARRHOEAGastrointestinal disorders | 0/19 | 0/62 | 3/41 | 0/39 | 0/41 | 0/40 |
| PERIPHERAL SWELLINGGeneral disorders | 1/19 | 0/62 | 1/41 | 0/39 | 0/41 | 0/40 |
| BRONCHITISInfections and infestations | 1/19 | 0/62 | 1/41 | 0/39 | 1/41 | 0/40 |
| SINUSITISInfections and infestations | 1/19 | 0/62 | 1/41 | 0/39 | 0/41 | 0/40 |
| TOOTH INFECTIONInfections and infestations | 1/19 | 0/62 | 0/41 | 1/39 | 0/41 | 1/40 |
| ANIMAL BITEInjury, poisoning and procedural complications | 1/19 | 0/62 | 0/41 | 0/39 | 0/41 | 0/40 |
| BLOOD GLUCOSE INCREASEDInvestigations | 1/19 | 0/62 | 0/41 | 0/39 | 0/41 | 0/40 |
Full Analysis Set: all randomized participants who received at least 1 dose of randomized study drug
| Age, Continuous(years) | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 57.6 ± 9.12 | 56.2 ± 12.82 | 59.2 ± 11.11 | 59.7 ± 10.95 | 58.1 ± 11.01 | 57.7 ± 10.60 | 58.0 ± 11.27 |
| Sex: Female, Male(Participants) | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 17 | 48 | 36 | 35 | 33 | 35 | 204 |
| Male | 2 | 14 | 5 | 4 | 8 | 5 | 38 |
| Race/Ethnicity, Customized(Participants) | ELS Placebo/UPA Placebo | UPA 15 mg/ELS 60 mg | ELS 60 mg/UPA Placebo | ELS 20 mg/UPA Placebo | ELS 5 mg/UPA Placebo | UPA 15 mg/ELS Placebo | Total |
|---|---|---|---|---|---|---|---|
| White | 19 | 58 | 36 | 35 | 35 | 37 | 220 |
| Black or African American | 0 | 3 | 4 | 4 | 3 | 3 | 17 |
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
| Multiple | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
Showing the first 100 of 115 sites across 9 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Oct 2018 to primary completion in Mar 2020, 17 months.
Results were first posted in May 2021, 1 year 1 month after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 17 months is close to that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elsubrutinib · Upadacitinib